In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap

15 Nov 2023

Agency sends letters to 10 companies saying they improperly listed patents in US FDA’s Orange Book covering drug-device combination products. FTC does not specify why it believes the patents were improperly listed.

FTC building — FTC objects to listing of drug-device combo patents in FDA's Orange Book • Source: Shutterstock

In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap

More from Legal & IP

More from Generics Bulletin